ArticlePostepy dermatologii i alergologii2025
Clinical curative effect and quality of life evaluation of dupilumab in treating children with atopic dermatitis and its effect on IgE levels, eosinophil count, Th2 cytokines (IL-4 and IL-13), and thymus and activation-regulated chemokine.
Article in Postepy dermatologii i alergologii, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Evidence-Based Clinical Recommendations on the Appropriateness of Prescriptions and Diagnostic Tests in Paediatric Allergology: Focus on IgE-Mediated and Non-IgE Mediated Food Allergy, Eosinophilic Gastrointestinal Disease, Urticaria, Angioedema and Atopic Dermatitis.Children (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Atopic dermatitis (AD) is a common chronic skin inflammatory disease. The traditional treatment shows limited effect and side effects. Dupilumab is a monoclonal antibody immunotherapy targeting IL-4 and IL-13, which may become a new direction for treating AD. Aim: This study was to explore the clinical curative effect of dupilumab in the treatment of children with AD, and its influence on the quality of life (QoL) of children. Material and methods: 54 children with AD, who were treated in the outpatient and inpatient departments of the hospital from August 2023 to July 2024, were included in this study. These children were treated with dupilumab, and their clinical curative effect as well as QoL were evaluated through relevant scales as well as the IgE, eosinophil counts, and Th2 cytokine levels. Results: After treatment, Eczema Area and Severity Index (EASI) score was 8.8 ±4.5, Scoring Atopic Dermatitis (SCORAD) score was 15.1 ±8.4, and itching Numeric Rating Scale (NRS) score was 1.1 ±0.7. Compared with those before treatment, the scores of 25.4 ±6.2, 38.6 ±10.3, and 6.9 ±2.2 were highly decreased with differences being statistically significant ( Conclusions: Dupilumab could effectively treat children with AD and improve their QoL, so it had a clinical application value.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.